Search

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more

Scientific Program Committee, EHA2025 Congress

Current committee members
Martin Dreyling, Germany (Chair)
Brian Huntly, United Kingdom (Past Chair)
Meritxell Alberich Jordà, Czechia (Chair elect)
Paolo Corradini, Italy (Local representative)
Gabriela Baerlocher, Switzerland
Valentine Brousse, France
Mattia D'Agostino, Italy
Mariane de Montalembert, France
Jordi Esteve, Spain
Thierry Facon, France
Thoas Fioretos, Sweden
Krzystof Giannopoulos, Poland
Shahram Kordasti, United Kingdom
Georg…

Read more

Previous winners, 2012–2022

2022 winners
Alexandre Fagnan
Junior Research Grant 2022
Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML

Samuele Ferrari
Junior Research Grant 2022
Innovative targeted base editing strategies for gene correction of WHIM syndrome

Lars Velten
Advanced Research Grant 2022
The role of the DNA methylation…

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Meet Robin Foà, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more